Currently, Tenax Therapeutics Inc [TENX] is trading at $15.9, down -12.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TENX shares have gain 21.19% over the last week, with a monthly amount glided 49.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tenax Therapeutics Inc [NASDAQ: TENX] stock has seen the most recent analyst activity on September 08, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $20. Previously, Leerink Partners started tracking the stock with Outperform rating on October 24, 2024, and set its price target to $16. On October 14, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $16 on the stock. William Blair started tracking the stock assigning a Outperform rating. Ladenburg Thalmann upgraded its rating to a Buy. MLV & Co started tracking with a Buy rating for this stock on December 16, 2014, and assigned it a price target of $7. In a note dated November 18, 2014, WallachBeth initiated an Buy rating and provided a target price of $12 on this stock.
This stock has fluctuated between a low of $4.63 and a high of $18.38 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $22.5 within the next 12 months. Tenax Therapeutics Inc [NASDAQ: TENX] shares were valued at $15.9 at the most recent close of the market. An investor can expect a potential return of 41.51% based on the average TENX price forecast.
Analyzing the TENX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.43 and Total Capital is -0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Tenax Therapeutics Inc [NASDAQ:TENX] is 15.58. As well, the Quick Ratio is 15.58, while the Cash Ratio is 15.06.
Transactions by insiders
Recent insider trading involved Rich Stuart, Chief Medical Officer, that happened on Dec 09 ’25 when 2500.0 shares were purchased. Chief Medical Officer, Rich Stuart completed a deal on Dec 08 ’25 to buy 2500.0 shares. Meanwhile, Chief Medical Officer Rich Stuart bought 2500.0 shares on Dec 04 ’25.
